Successful Treatment with High-dose Steroids for Acute Exacerbation of Idiopathic Pulmonary Fibrosis Triggered by COVID-19

We herein report a case of acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) triggered by COVID-19. An 87-year-old woman tested positive for COVID-19 on a polymerase chain reaction test, and computed tomography revealed ground-glass opacity (GGO) superimposed on a background pattern consi...

Descripción completa

Detalles Bibliográficos
Autores principales: Omote, Norihito, Kanemitsu, Yoshihiro, Inoue, Takahiro, Yonezawa, Toshiyuki, Ichihashi, Takuji, Shindo, Yuichiro, Sakamoto, Koji, Ando, Akira, Suzuki, Atsushi, Niimi, Akio, Ito, Satoru, Imaizumi, Kazuyoshi, Hashimoto, Naozumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851168/
https://www.ncbi.nlm.nih.gov/pubmed/34744107
http://dx.doi.org/10.2169/internalmedicine.8163-21
Descripción
Sumario:We herein report a case of acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) triggered by COVID-19. An 87-year-old woman tested positive for COVID-19 on a polymerase chain reaction test, and computed tomography revealed ground-glass opacity (GGO) superimposed on a background pattern consistent with usual interstitial pneumonia. Considering these data, we diagnosed her with AE-IPF. She experienced worsening of dyspnea and expansion of the GGO. Therefore, we introduced high-dose steroids (methylprednisolone 250 mg/day for 3 days). After the treatment, the pulmonary infiltrates improved. She was discharged from our hospital without severe disability. High-dose steroids can be a viable treatment option for AE-IPF triggered by COVID-19.

Ejemplares similares